Corcept TherapeuticsCORT +2.14%82 Days Payable is 1,167.13 as of Mar. 2026, which is 98% above its 10-year median of 590.48. GuruFocus rates CORT with a GF Score™ of 82/100 and a GF Value™ of $61.59 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 708 Biotechnology companies, Corcept Therapeutics ranks better than 84.6% on this metric.
The historical rank and industry rank for Corcept Therapeutics's Days Payable or its related term are showing as below:
CORT'
s Days Payable Range Over the Past 10 Years
Min: 320.57 Med: 590.48 Max: 866.15
Current: 866.15
During the past 13 years, Corcept Therapeutics's highest Days Payable was 866.15. The lowest was 320.57. And the median was 590.48.
CORT's Days Payable is ranked better than 84.6% of 708
companies
in the Biotechnology industry
Industry Median: 113.56
vs CORT: 866.15
Corcept Therapeutics's Days Payable
increased
from Mar. 2025 (822.56) to Mar. 2026 (1,167.13).
It may suggest that Corcept Therapeuticsdelayed paying its suppliers.
Corcept Therapeutics Days Payable Related Terms
Corcept Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Corcept Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Corcept Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (CORT) has a Days Payable of 1,167.13 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Corcept Therapeutics and its competitors. This is 98% above median its historical median of 590.48. Over the past decade, Corcept Therapeutics' Days Payable has ranged from 320.57 to 866.15. According to the industry distribution chart, Corcept Therapeutics ranks #109 out of 708 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Corcept Therapeutics' Days Payable too high?
Corcept Therapeutics' current Days Payable of 1,167.13 is 98% above median its 10-year median of 590.48. Over the past 10 years, this metric has ranged from a low of 320.57 to a high of 866.15. The Biotechnology industry median Days Payable is 113.56. Corcept Therapeutics' value of 1,167.13 is 927.8% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #109 out of 708 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Days Payable compare to PCVX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #109 out of 708 companies for Days Payable. This places Corcept Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Corcept Therapeutics' value of 1,167.13 is 927.8% above this benchmark. Historically, Corcept Therapeutics' own Days Payable has ranged from 320.57 to 866.15 over the past decade. While the company's 10-year median is 590.48 vs. the industry median of 113.56, Corcept Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Days Payable of 1,167.13 is 927.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Days Payable is 1,167.13, which is 98% above median its own 10-year median of 590.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $61.59, compared to a current price of $81.56 — trading 32.4% above its estimated fair value. The current Days Payable is 1,167.13, which is 98% above median its 10-year median of 590.48 and 927.8% above the Biotechnology industry median of 113.56. Corcept Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Days Payable is 1,167.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $81.56 is trading 32.4% above its estimated GF Value™ of $61.59.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Days Payable: 1,167.13 (98% above median its 10-year median of 590.48)
GF Value™: $61.59 vs. price of $81.56 (32.4% above fair value)
Industry Position: 927.8% above the Biotechnology median (#109 of 708)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for CORT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
